Table 1 Comparative analysis between frail and non-frail patients with CRC, according to the CSHA-CSF scale
Variable | Total N (%) 149 (100) | No frailty N (%) 90 (60.4%) | Frailty N (%) 59 (39.6%) | P |
|---|---|---|---|---|
Age | ||||
Median (IQR) | 75 (72–80) | 74 (72–29) | 77 (73–81) | 0.008* |
Gender | ||||
Men | 96 (64.4) | 61 (67.8) | 35 (59.3) | 0.292 |
Women | 53 (35.6) | 29 (32.2) | 24 (40.7) | |
ASA | ||||
I–II | 47 (31.5) | 32 (35.6) | 15 (25.4) | 0.193 |
III–IV | 102 (68.5) | 58 (64.4) | 44 (74.6) | |
Charlson Index | ||||
Median (IQR) | 3.0 (2.0–4.0) | 2.0 (2.0–4.0) | 3.0 (2.0–4.0) | 0.005* |
Barthel | ||||
< 80 | 14 (9.4) | 1 (1.1) | 13 (22.0) | < 0.001* |
≥ 80 | 135 (90.6) | 89 (98.9) | 46 (78.0) | |
Lawton-Brody | ||||
Median (IQR) | 6.0 (5.0–8.0) | 7.0 (6.0–8.0) | 4.0 (3.0–6.0) | < 0.001* |
Pfeiffer | ||||
< 3 | 140 (94.0) | 89 (98.9) | 51 (86.4) | 0.003* |
≥ 3 | 9 (6.0) | 1 (1.1) | 8 (13.6) | |
BMIa | ||||
Mean ± SD | 26.8 (± 4.0) | 26.9 (± 4.2) | 26.5 (± 3.7) | 0.746 |
MNAb | ||||
Median–IQR | 10.0 (9.0–12.0) | 11.0 (9.0–13.0) | 10.0 (9.0–12.0) | 0.185 |
Hemoglobin gr/dL | ||||
Mean (±SD) | 12.5 (± 2.2) | 12.6 (± 2.1) | 12.3 (± 2.2) | 0.507 |
Creatinine mg/dL | ||||
Median (IQR) | 0.96 (0.79–1.13) | 0.96 (0.82–1.06) | 0.97 (0.75–1.22) | 0.840 |
Albumin gr/dL | ||||
Mean (±SD) | 3.8 (± 0.5) | 3.8 (± 0.5) | 3.8 (± 0.5) | 0.963 |
Laparoscopic approach | ||||
n (%) | 56 (38.9) | 30 (53.6) | 26 (46.4) | 0.230 |
Anastomosis | ||||
No | 22 (14.8) | 13 (14.4) | 9 (15.3) | 0.892 |
Yes | 127 (85.2) | 77 (85.6) | 50 (84.7) | |
Transfusions | ||||
No | 116 (77.9) | 71 (78.9) | 45 (76.3) | 0.707 |
Yes | 33 (22.1) | 19 (21.1) | 14 (23.7) | |
T | ||||
1–2 | 45 (30.2) | 25 (27.8) | 20 (33.9) | 0.426 |
3–4 | 104 (69.8) | 65 (72.2) | 39 (66.1) | |
N | ||||
0 | 102 (68.5) | 60 (66.7) | 42 (71.2) | 0.561 |
1 | 47 (31.5) | 30 (33.3) | 17 (28.8) | |
M | ||||
0 | 142 (95.3) | 87 (96.7) | 55 (93.2) | 0.436 |
1 | 7 (4.7) | 3 (3.3) | 4 (6.8) | |
TNM stage | ||||
I–II | 99 (66.4) | 59 (65.6) | 40 (67.8) | 0.777 |
III–IV | 50 (33.6) | 31 (34.4) | 19 (32.2) | |
Anastomosis dehiscence | ||||
No | 139 (93.3) | 86 (95.6) | 53 (89.8) | 0.195 |
Yes | 10 (6.7) | 4 (4.4) | 6 (10.2) | |
CCI ≥ 1c | ||||
Median (IQR) | 33.3 (8.7–46.3) | 21.8 (8.7–41.3) | 32.4 (20.9–55.4) | 0.04* |
Hospital stay | ||||
Median (IQR) | 10 (7–15) | 10 (7–16) | 9 (7–15) | 0.259 |
Chemotherapy | ||||
No | 112 (75.2) | 60 (66.7) | 52 (88.1) | 0.003* |
Yes | 37 (24.8) | 30 (33.3) | 7 (11.9) | |
30-day mortality | ||||
No | 144 (96.6) | 90 (100.0) | 54 (91.5) | 0.009* |
Yes | 5 (3.4%) | 0 (0.0) | 5 (8.5) | |
90-day mortality | ||||
No | 137 (91.9) | 85 (94.4) | 52 (88.1) | 0.166 |
Yes | 12 (8.1) | 5 (5.6) | 7 (11.9) | |
1-year mortality | ||||
No | 130 (87.2) | 80 (88.9) | 50 (84.7) | 0.458 |
Yes | 19 (12.8) | 10 (11.1) | 9 (15.3) | |
Cumulative survival at 5 years | ||||
(mean months) | 62.16 | 63.9 | 58.9 | 0.246 |
Death from non-tumoral causes | ||||
n (%) | 21 (43.8) | 11 (42.3) | 16 (72.7) | 0.034* |